BioSpace News Archive

Sonelokimab showed significant clinical benefit with rapid onset and a good safety profile, with clear skin (PASI 100) achieved in up to 57% of patients at Week 24 and sustained responses over 52 weeks

Bausch Health Companies Inc. announced that the Company will participate in multiple upcoming investor conferences.

Ionis Pharmaceuticals, Inc. announced that management will participate in virtual fireside chats at the following investor conferences

ESSA Pharma Inc. today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2021.

Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests.

XOMA Corporation (Nasdaq: XOMA) reported its first quarter 2021 financial results and provided a recent operations update.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (“CBN”), will report financial results on Thursday, May 13, 2021 for the third quarter of fiscal year 2021 ending March 31, 2021. Conference Call & Webcast*: Thursday, May 13, 2021 at 8:00 AM Pacific Time, 11:00 am

– Received U.S. Food and Drug Administration (FDA) approval for NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency ( MoCD) Type A – Reported pr oof-of-concept data of encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) –

- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - Well-Resourced with Cash Runway Expected into the Second Half of 2024 -

Enrolling Patients in Phase 3 Trial of SY-1425 in Combination with Azacitidine in RARA-Positive Newly Diagnosed Higher-Risk MDS Patients Today Announced Three-Part KOL Webinar Series on Its Portfolio of Investigational Targeted Hematology Therapies, Beginning May 2021 On Track to Achieve 2021 Milestones, Including Initiation of SY-1425 and SY-2101 Clinical Trials in 2H 2021 and Additional Dose-Escalation Data for SY-5609 in 3Q 2021